Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today launched a new online U.S. product catalog, available at Hospira.com/catalog. Developed with input from customers, the new website allows healthcare facilities and other medical care providers to search Hospira's more than 1,200 products in a variety of ways – alphabetically, by product name, list number, or therapeutic class.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hospira/48828/
The first comprehensive long-term study comparing different medications for type 2 diabetes is launching nationwide. The GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study will compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64578-grade-glycemia-reduction-approaches-in-diabetes-comparative-effectiveness
A new survey from the Gout & Uric Acid Education Society (GUAES) finds many Americans with gout may be placing too much emphasis on diet when it comes to managing the disease and controlling painful flares. Of all the steps taken to manage gout, respondents cited changing their diet by eliminating or reducing consumption of certain foods as their top step taken (50 percent)—even ahead of taking medications to lower their uric acid levels (40 percent) and maintaining an overall healthy fitness level (33 percent). Furthermore, nearly one in three with gout incorrectly believes that the disease can be completely avoided by eliminating certain foods; and more than one in four said they would not take medications if they were making dietary changes.
“Physicians all too often see patients who believe they can successfully manage their gout with diet alone,” said N. Lawrence Edwards, M.D., a rheumatologist and GUAES chairman. “But even with extremely rigid diet restrictions, most gout patients will only be able to lower their uric acid levels slightly—not nearly enough to achieve a healthy level to control flares and reduce risk for long-term damage.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7835451-guaes-diet-survey/
Vioxx Settlement
This is an important announcement for consumers about the prescription drug Vioxx. Vioxx was a drug commonly used to treat pain and inflammation in adults with arthritis.
A settlement was reached with the manufacturer of Vioxx and will provide refunds to anyone who paid for the medication. Consumers are eligible to get $50 or more. Personal injury claims related to this drug are not included in this settlement.
The deadline to file a claim is approaching – claims must be filed by May 6, 2014.
Details are available at http://www.VioxxSettlement.com or by calling 1-866-439-6932.
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
http://www.getthehormonecure.com Dr.
Sara Gottfried refuses to accept the traditional medical thinking that
feeling cranky, asexual, tapped out, and sleep-deprived is just part of
being female and aging, and that prescription medication will fix all
problems. In The Hormone Cure, she combines natural therapies with
rigorous scientific testing to help women feel fully alive, especially
in the years prior to menopause. Using an informative questionnaire to
identify common symptoms of hormonal imbalance such as insomnia, low
sex drive, lack of energy, moodiness, hot flashes, and more; detailing
causes; and offering solutions in non-judgmental and thoughtful
language, Dr. Gottfried provides a novel plan based on solid scientific
research. She believes you don't find a cure at the bottom of a pill
bottle.
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
As the rate of teen prescription drug abuse continues to rise in the United States, the National Association of School Nurses (NASN) and Janssen Pharmaceuticals, Inc., today joined with addiction expert Dr. Drew Pinsky,* to launch a new tool kit intended to help America’s schools educate teens and their parents about the risks and consequences of abusing prescription medication.
The Schools Get Smart, Schools Take Action Tool Kit is part of Smart Moves, Smart Choices, a national initiative of NASN and Janssen Pharmaceuticals, Inc., designed to inform parents, teens and educators about this growing problem of teen prescription drug abuse, and what they can do to combat it.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/smartmovessmartchoices/51444/
The thinking that diet does not affect acne is a falsehood perpetuated by that part of the medical industry that is trying to protect their livelihood of dispensing drugs. The AMA has established that the only way to deal with acne is through the use of medication. They say there is no evidence to support the idea that diet causes acne.
Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off “Join the Pace Makers,” a national campaign designed to empower people with a condition called bradycardia, also known as a slow heartbeat, to learn about their available treatment options so that they can have an informed conversation with their doctor.
People living with bradycardia can experience a number of symptoms ranging from general lethargy and shortness of breath to fainting or syncope. There are a number of treatment options available, including medication therapy and implanting a pacemaker, which delivers electrical pulses to help regulate a person’s heartbeat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52990-debbie-allen-and-medtronic-join-the-pace-makers
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
